Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05005273 | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 12 | Feb 28, 2024 | clinicaltrials |
| NCT04577638 | Accelerated Radio-Immunotherapy for Lung Cancer(AIRING) | completed | Phase 2 | 8 | Center Eugene MarquisOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT01542437 | Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 66 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02073968 | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer(PAINT) | completed | Phase 2 | 35 | Albert Einstein College of MedicineOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02567799 | BIO 300 Non-Small Cell Lung Cancer Study(NSCLC) | completed | Phase 1 / Phase 2 | 21 | Humanetics CorporationINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT03087760 | Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer | completed | Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03083691 | BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer | completed | Phase 2 | 90 | Lung Cancer Group CologneOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04620330 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer(RAMP202) | completed | Phase 2 | 90 | Verastem, Inc.INDUSTRY | 5 | Jan 12, 2024 | clinicaltrials |
| NCT02581943 | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | completed | Phase 2 | 43 | Wake Forest University Health SciencesOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04271384 | Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer | completed | Phase 2 | 25 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT03845270 | Her2-positive Lung Cancer Treated With Dedicated Drug(R2D2) | completed | Phase 2 | 46 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT04311034 | A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 37 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03014648 | Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 28 | Liza Villaruz, MDOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | completed | Phase 2 | 27 | Joel NealOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02716038 | Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | completed | Phase 2 | 39 | Columbia UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT02183883 | Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity(DARWIN1) | completed | Phase 2 | 12 | University College, LondonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03409458 | A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab(PAVE-1) | completed | Phase 1 / Phase 2 | 68 | Promontory Therapeutics Inc.INDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT01750281 | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.(SELECT-2) | completed | Phase 2 | 212 | AstraZenecaINDUSTRY | 8 | Oct 24, 2023 | clinicaltrials |
| NCT03727724 | Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer(AFACET) | completed | Phase 2 | 37 | The Netherlands Cancer InstituteOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03434418 | A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations | completed | Phase 2 | 17 | Duke UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03468985 | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00590902 | Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT02426658 | Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02904954 | Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer | completed | Phase 2 | 60 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT00602797 | Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02803203 | Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02439450 | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 121 | Heat BiologicsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02343952 | Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | completed | Phase 2 | 93 | Nasser Hanna, M.D.OTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | completed | Phase 1 / Phase 2 | 29 | Gritstone bio, Inc.INDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | completed | Phase 1 / Phase 2 | 39 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT04345146 | Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC | completed | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT03083808 | Phase II Trial of Continuation Therapy in Advanced NSCLC | completed | Phase 2 | 35 | Greg Durm, MDOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT03513666 | A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment(JS001) | completed | Phase 2 | 40 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT03840915 | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 70 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Aug 21, 2023 | clinicaltrials |
| NCT01708993 | Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy | completed | Phase 2 | 166 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03520842 | Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | completed | Phase 2 | 121 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2023 | clinicaltrials |
| NCT02980991 | Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) | completed | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT01833572 | Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | completed | Phase 2 | 36 | Fudan UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05116891 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Cantargia ABINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT01824901 | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01104155 | Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 123 | Eisai Inc.INDUSTRY | 7 | Jun 22, 2023 | clinicaltrials |
| NCT01126736 | Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 98 | Eisai Inc.INDUSTRY | 5 | Jun 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 28, 2024source: clinicaltrials